GlassScriptPhysician profile
Jennifer Cameron
NPI 1790256733
$5,139.82
in general payments reported to CMS, 2019-2025
37 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $551 · 2022: $506 · 2023: $360 · 2024: $2,112 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,983 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,982.98 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,069.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $608.04 | 2021-2025 | |
| Pfizer INC. | $557.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $512.50 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $305.55 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $302.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $267.03 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $213.21 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $183.72 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $119.22 | 2022-2025 | Otezla, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.56 | 2021-2025 | Xifaxan, Trulance |
| Lundbeck LLC | $94.40 | 2024-2025 | Vyepti, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.84 | 2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.64 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $57.78 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.20 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Inspire Medical Systems, INC. | $53.32 | 2024-2025 | Inspire |
| Tris Pharma INC | $52.55 | 2024 | Dyanavel Xr |
| Cequr Corporation | $46.51 | 2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $44.96 | 2022-2023 | |
| Gilead Sciences, INC. | $42.93 | 2022 | |
| Dexcom, INC. | $42.25 | 2024-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $39.01 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $33.51 | 2024 | Austedo Xr |
| Verrica Pharmaceuticals INC. | $22.72 | 2024 | Ycanth |
| Phathom Pharmaceuticals, INC. | $19.99 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $19.93 | 2025 | Heplisav-B |
| Almatica Pharma LLC | $18.64 | 2024 | Loreev Xr |
| Seqirus USA INC | $18.51 | 2025 | Fluad, Flucelvax |
| Arbor Pharmaceuticals, INC. | $17.84 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.64 | 2024 | Trintellix |
| Beta Bionics, INC. | $16.03 | 2024 | Ilet Bionic Pancreas |
| Eisai INC. | $15.64 | 2025 | |
| Shield Therapeutics INC | $14.95 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.07 | 2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $13.95 | 2024 | Quviviq |
| Sumitomo Pharma America, INC. | $12.62 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.